Boehringer Ingelheim licenses drug targets from autoimmune collaboration with Galapagos
Galapagos NV announced that Boehringer Ingelheim has exercised its right to license two drug targets from the autoimmune research agreement with Galapagos' BioFocus DPI service division, resulting in a milestone payment to Galapagos.
This is the second milestone reached in the three-year collaboration initially announced in January 2006. In the collaboration, BioFocus DPI applied its SilenceSelect® shRNA-based gene collection to run a target discovery screen for Boehringer Ingelheim's autoimmune discovery research. BioFocus DPI obtained upfront fees, research and development funding and will receive milestone fees when certain drug discovery criteria are met. Should all criteria on a target be achieved, total potential contract value for BioFocus DPI may exceed EUR2 million per target.
"We are delighted that targets identified through our shRNA screening approach have met Boehringer's selection criteria," said Onno van de Stolpe, Chief Executive Officer of Galapagos. "This is further testament that the target discovery research performed at Galapagos and BioFocus DPI meets the standards of the world's leading pharmaceutical companies."
Other news from the department business & finance
